Government of Canada commits $18.2 million to Precision NanoSystems to develop COVID-19 vaccine

22 October 2020
Client work

On October 22, 2020, Precision Nanosystems, Inc. ("PNI") announced that it had received a commitment of up to $18.2 million from the Government of Canada under the Innovation, Science and Economic Development's (ISED) Strategic Innovation Fund (SIF) to develop a COVID-19 vaccine.

PNI is a global leader in ushering in the next wave of genetic medicines in infectious diseases, cancer and rare diseases. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genetic medicines.

Paul Armitage of Gowling WLG advised PNI with respect to the negotiation of this contribution agreement with the Government of Canada.

NOT LEGAL ADVICE. Information made available on this website in any form is for information purposes only. It is not, and should not be taken as, legal advice. You should not rely on, or take or fail to take any action based upon this information. Never disregard professional legal advice or delay in seeking legal advice because of something you have read on this website. Gowling WLG professionals will be pleased to discuss resolutions to specific legal concerns you may have.
Related   Life Sciences

Related Insights & Resources

View all insights Related Insights & Resources
Client work
13 September 2021 Providence Therapeutics and Everest Medicines enter into comprehensive agreements to advance mRNA vaccines and therapies in Asia emerging markets
Articles
24 August 2021 Is an NDA a useful tool when doing business in China?
Syringe and medical vile on desk Articles
04 August 2021 Only the excess – Federal Court of Appeal criticizes PMPRB for engaging in consumer protection

Team

Download or print PDF